Top Markets
Coin of the day
Quest PharmaTech Inc. Quest PharmaTech Inc.

Quest PharmaTech Inc.

QPTFF
Rangering i aksjer #35835
Quest PharmaTech Inc. (QPTFF), an Edmonton, Canada-based pharmaceutical firm,... Quest PharmaTech Inc. (QPTFF), an Edmonton, Canada-based pharmaceutical firm, specializes in creating antibody-driven immunotherapeutic remedies primarily for various cancers. A cornerstone of its product pipeline is Mab AR 9.6, an advanced therapeutic candidate specifically designed to target truncated O-glycans on MUC16 for precise cancer treatment applications. The company's offerings further encompass Oregovomab, an anti-CA-125 antibody that has successfully completed Phase II clinical trials for the management of ovarian cancer. Beyond these specific agents, Quest PharmaTech is actively involved in the development, manufacturing, and commercialization of new immunotherapy products aimed at combating pancreatic cancer. The organization also diversifies its portfolio by utilizing proprietary transdermal delivery technologies to formulate products for dermatological conditions and wound healing. Additionally, it develops specialized skin-penetrating active molecules for use in both cosmetic and pharmaceutical goods. Rounding out its innovative efforts, Quest PharmaTech designs intricate combinatorial immunotherapies for cancer, employing monoclonal antibodies belonging to both immunoglobulin G and E classes.
Aksjekurs
$0.02
Sist synkronisert: 2026-08-13
Markedsverdi
$3.38M
Endring (1 dag)
0.00%
Endring (1 år)
50.38%
Land
CA
Handel Quest PharmaTech Inc. (QPTFF)

Kategori

P/S-forhold for Quest PharmaTech Inc. (QPTFF)
P/S-forhold per 2026 TTM: 0
Ifølge Quest PharmaTech Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for Quest PharmaTech Inc. fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE